News & Updates
Showing Multidisciplinary articles
Showing
Two DOACs show similar bleeding risks in head-to-head VTE trial
In a post hoc analysis of the RENOVE trial, the direct oral anticoagulants (DOACs) rivaroxaban and apixaban demonstrate comparable risks of clinically relevant bleeding (CRB) and recurrent venous thromboembolism (VTE). These were observed across the crude, adjusted, and IPTW* analyses.
Two DOACs show similar bleeding risks in head-to-head VTE trial
23 Dec 2025
Insulin glargine improves glycaemic control in T2D patients in India
Findings from the prospective PRIMARY-INDIA study presented at ATTD-Asia 2025 show clinically meaningful improvements in glycaemic control with insulin glargine in individuals with type 2 diabetes (T2D) in primary care settings, with a consistent safety profile.
Insulin glargine improves glycaemic control in T2D patients in India
22 Dec 2025
1L osimertinib for EGFRm NSCLC: Who are the long-term responders?
A retrospective study by researchers from the Chinese University of Hong Kong has found that patients with EGFR mutation–positive (EGFRm) non-small-cell lung cancer (NSCLC) who had a good performance status (PS) and no brain, liver or bone metastases at diagnosis had lower odds of progression or death at 2 years with osimertinib monotherapy. Furthermore, patients with oligoprogressive disease (OPD) had better outcomes than those with systemic progressive disease (SPD), and local ablative therapy (LAT) was shown to effectively defer switching systemic therapy in patients with OPD.